307 related articles for article (PubMed ID: 36559036)
1. Gastrointestinal Permeation Enhancers for the Development of Oral Peptide Pharmaceuticals.
Kim JC; Park EJ; Na DH
Pharmaceuticals (Basel); 2022 Dec; 15(12):. PubMed ID: 36559036
[TBL] [Abstract][Full Text] [Related]
2. Intestinal Permeation Enhancers for Oral Delivery of Macromolecules: A Comparison between Salcaprozate Sodium (SNAC) and Sodium Caprate (C
Twarog C; Fattah S; Heade J; Maher S; Fattal E; Brayden DJ
Pharmaceutics; 2019 Feb; 11(2):. PubMed ID: 30781867
[TBL] [Abstract][Full Text] [Related]
3. Transient Permeation Enhancer® (TPE®) technology for oral delivery of octreotide: a technological evaluation.
Brayden DJ; Maher S
Expert Opin Drug Deliv; 2021 Oct; 18(10):1501-1512. PubMed ID: 34128734
[TBL] [Abstract][Full Text] [Related]
4. Gastrointestinal Permeation Enhancers Beyond Sodium Caprate and SNAC - What is Coming Next?
Bohley M; Leroux JC
Adv Sci (Weinh); 2024 Jun; ():e2400843. PubMed ID: 38884149
[TBL] [Abstract][Full Text] [Related]
5. Oral Absorption of Middle-to-Large Molecules and Its Improvement, with a Focus on New Modality Drugs.
Asano D; Takakusa H; Nakai D
Pharmaceutics; 2023 Dec; 16(1):. PubMed ID: 38258058
[TBL] [Abstract][Full Text] [Related]
6. Development and evaluation of C10 and SNAC erodible tablets for gastric delivery of a GIP/GLP1 peptide in monkeys.
Tran H; Dogra M; Huang S; Aihara E; ElSayed M; Aburub A
Int J Pharm; 2024 Jan; 650():123680. PubMed ID: 38070657
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the physicochemical interactions between exenatide and two intestinal permeation enhancers: Sodium caprate (C
Twarog C; Fattal E; Noiray M; Illel B; Brayden DJ; Taverna M; Hillaireau H
Int J Pharm; 2022 Oct; 626():122131. PubMed ID: 36028084
[TBL] [Abstract][Full Text] [Related]
8. Salcaprozate sodium (SNAC) enhances permeability of octreotide across isolated rat and human intestinal epithelial mucosae in Ussing chambers.
Fattah S; Ismaiel M; Murphy B; Rulikowska A; Frias JM; Winter DC; Brayden DJ
Eur J Pharm Sci; 2020 Nov; 154():105509. PubMed ID: 32777258
[TBL] [Abstract][Full Text] [Related]
9. A head-to-head Caco-2 assay comparison of the mechanisms of action of the intestinal permeation enhancers: SNAC and sodium caprate (C
Twarog C; Liu K; O'Brien PJ; Dawson KA; Fattal E; Illel B; Brayden DJ
Eur J Pharm Biopharm; 2020 Jul; 152():95-107. PubMed ID: 32387703
[TBL] [Abstract][Full Text] [Related]
10. In Silico-Based Experiments on Mechanistic Interactions between Several Intestinal Permeation Enhancers with a Lipid Bilayer Model.
Kneiszl R; Hossain S; Larsson P
Mol Pharm; 2022 Jan; 19(1):124-137. PubMed ID: 34913341
[TBL] [Abstract][Full Text] [Related]
11. SNAC for Enhanced Oral Bioavailability: An Updated Review.
Kommineni N; Sainaga Jyothi VGS; Butreddy A; Raju S; Shapira T; Khan W; Angsantikul P; Domb AJ
Pharm Res; 2023 Mar; 40(3):633-650. PubMed ID: 36539668
[TBL] [Abstract][Full Text] [Related]
12. Physical and barrier changes in gastrointestinal mucus induced by the permeation enhancer sodium 8-[(2-hydroxybenzoyl)amino]octanoate (SNAC).
Mortensen JS; Bohr SS; Harloff-Helleberg S; Hatzakis NS; Saaby L; Nielsen HM
J Control Release; 2022 Dec; 352():163-178. PubMed ID: 36314534
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the effects of the intestinal permeation enhancers, SNAC and sodium caprate (C
Twarog C; McCartney F; Harrison SM; Illel B; Fattal E; Brayden DJ
Eur J Pharm Sci; 2021 Mar; 158():105685. PubMed ID: 33359131
[TBL] [Abstract][Full Text] [Related]
14. Absence of QTc Prolongation with Sodium N-(8-[2-Hydroxybenzoyl] Amino) Caprylate (SNAC), an Absorption Enhancer Co-Formulated with the GLP-1 Analogue Semaglutide for Oral Administration.
Granhall C; Bækdal TA; Breitschaft A; Søndergaard FL; Anderson TW; Thomsen M
Diabetes Ther; 2021 Sep; 12(9):2599-2610. PubMed ID: 34319564
[TBL] [Abstract][Full Text] [Related]
15. A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes.
Aroda VR; Blonde L; Pratley RE
Rev Endocr Metab Disord; 2022 Oct; 23(5):979-994. PubMed ID: 35838946
[TBL] [Abstract][Full Text] [Related]
16. Current Understanding of Sodium N-(8-[2-Hydroxylbenzoyl] Amino) Caprylate (SNAC) as an Absorption Enhancer: The Oral Semaglutide Experience.
Solis-Herrera C; Kane MP; Triplitt C
Clin Diabetes; 2024; 42(1):74-86. PubMed ID: 38230324
[TBL] [Abstract][Full Text] [Related]
17. Oral delivery of proteins and peptides: Challenges, status quo and future perspectives.
Zhu Q; Chen Z; Paul PK; Lu Y; Wu W; Qi J
Acta Pharm Sin B; 2021 Aug; 11(8):2416-2448. PubMed ID: 34522593
[TBL] [Abstract][Full Text] [Related]
18.
Tran H; Aihara E; Mohammed FA; Qu H; Riley A; Su Y; Lai X; Huang S; Aburub A; Chen JJH; Vitale OH; Lao Y; Estwick S; Qi Z; ElSayed MEH
Mol Pharm; 2023 Feb; 20(2):929-941. PubMed ID: 36592951
[TBL] [Abstract][Full Text] [Related]
19. Evaluation in pig of an intestinal administration device for oral peptide delivery.
Berg S; Uggla T; Antonsson M; Nunes SF; Englund M; Rosengren L; Fahraj M; Wu X; Govender R; Söderberg M; Janzén D; Van Zuydam N; Hugerth A; Larsson A; Abrahmsén-Alami S; Abrahamsson B; Davies N; Bergström CAS
J Control Release; 2023 Jan; 353():792-801. PubMed ID: 36493948
[TBL] [Abstract][Full Text] [Related]
20. Interactions of oral permeation enhancers with lipid membranes in simulated intestinal environments.
Larsen NW; Kostrikov S; Hansen MB; Hjørringgaard CU; Larsen NB; Andresen TL; Kristensen K
Int J Pharm; 2024 Apr; 654():123957. PubMed ID: 38430950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]